Results 61 to 70 of about 29,746 (162)

Retaining, and Enhancing, the QALY

Качественная клиническая практика, 2018
.
Joseph Lipscomb, Michael Drummond, Dennis Fryback, Marthe Gold, Dennis Revick, I. A. Vilum, S. L. Plavinskii, D. Yu. Belousov   +7 more
doaj  

The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health

Journal of Comparative Effectiveness Research
Since late 2020, the Canadian Agency of Drugs and Technologies in Health (CADTH) has been using a threshold of $50,000 (CAD) per quality-adjusted life-year (QALY) for both oncology and non-oncology drugs. When used for oncology products, this threshold
Chakrapani Balijepalli, Lakshmi Gullapalli, Juhi Joshy, Nigel SB Rawson   +3 more
doaj   +1 more source

Immune checkpoint inhibitors-based therapies for first-line treatment of advanced ovarian cancer with non-BRCAm/HRD-negative: a cost-effectiveness analysis

Journal of Ovarian Research
Background Emerging evidence supports the clinical potential of immune checkpoint inhibitors (ICIs) with or without bevacizumab and poly-(adenosine diphosphate-ribose) polymerase (PARP) inhibitors for refractory advanced ovarian cancer (AOC) with BRCA ...
Youwen Zhu, Xiaofang Zhou, Kun Liu, Hong Zhu   +3 more
doaj   +1 more source

Toward a Consensus on the QALY

Качественная клиническая практика, 2018
.
Michael Drummond, Diana Brixner, Marthe Gold, Paul Kind, Alistair Mcguire, Erik Nord, I. A. Vilum, D. Yu. Belousov   +7 more
doaj  

Gute Qalys, schlechte Qalys? [PDF]

Gesundheits- und Sozialpolitik, 2007
openaire   +1 more source

Global evidence on the cost-effectiveness of cardiac resynchronization therapy for heart failure: a systematic review. [PDF]

Front Cardiovasc Med
Bajraktari K, Ademi Z, Bajraktari A, Bajrami R, Kryeziu B, Gil RJ, Henein MY, Bajraktari G.   +7 more
europepmc   +1 more source

Cost-Effectiveness Analysis of ¹⁷⁷Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective. [PDF]

J Nucl Med
Gogebakan KC, Kunst N, Ghodsi A, Owens L, Iravani A, Etzioni R.   +5 more
europepmc   +1 more source

Value-based pricing of tislelizumab plus chemotherapy versus chemotherapy alone for advanced oesophageal squamous cell carcinoma: a Markov modelling study from the US payer perspective. [PDF]

BMJ Open
Abdeen AA, Ayer T, Lim F, Shue S, Hur C.
europepmc   +1 more source

Economic evaluation of the second-line regimen of liposome irinotecan (II) combined with 5-FU/LV versus placebo combined with 5-FU/LV for locally advanced or metastatic pancreatic ductal adenocarcinoma in China. [PDF]

PLoS One
Huang J, Ye H, Lin J, Luo D, Huang P, Zheng X.   +5 more
europepmc   +1 more source

Economic evaluations of preventive interventions for self-harm and suicide: a systematic review. [PDF]

Psychol Med
Le LK, Le DQ, Le PH, Tan EJ, Neil A, Andriessen K, Pirkis J, Mihalopoulos C, Reifels L.   +8 more
europepmc   +1 more source